This information is intended for Colorado Prescribers
HB 19-1131
| MARKETED PRESCRIPTION DRUG | COLORADO WAC DISCLOSURE FORM | DATE UPDATED |
|---|---|---|
| Diabetes Products | Form | 1/4/2022 |
| Vaccines | Form | 1/4/2022 |
| ALDURAZYME® (laronidase) | Form | 1/15/2021 |
| ALPROLIX® [Coagulation factor IX (recombinant), Fc fusion protein] | Form | 1/4/2022 |
| AUBAGIO® (teriflunomide) | Form | 1/4/2022 |
| CABLIVI® (caplacizumab-yhdp) | Form | 1/4/2022 |
| CERDELGA® (eliglustat) capsules, for oral use | Form | 1/15/2021 |
| Cerezyme® (imiglucerase for injection) | Form | 1/15/2021 |
| DUPIXENT® (dupilumab) Injection | Form | 1/4/2022 |
| ELITEK® (rasburicase) for injection | Form | 1/4/2022 |
| ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein] | Form | 1/4/2022 |
| FABRAZYME® (agalsidase beta) for injection, for intravenous use | Form | 1/15/2021 |
| JEVTANA® (cabazitaxel) Injection | Form | 1/4/2022 |
| KEVZARA® (sarilumab) | Form | 1/4/2022 |
| LEMTRADA® (alemtuzumab) | Form | 1/4/2022 |
| LIBTAYO® (cemiplimab - rwlc) | Form | 8/06/2021 |
| LOVENOX® (enoxaparin sodium injection) | Form | 1/06/2021 |
| LUMIZYME® (alglucosidase alfa) | Form | 4/25/2021 |
| Mozobil® (plerixafor injection) | Form | 1/4/2022 |
| MULTAQ® (dronedarone) | Form | 1/4/2022 |
| NEXVIAZYME (avalglucosidase alfa-ngpt) for injection, for intravenous use | Form | 8/17/2021 |
| SARCLISA® (isatuximab-irfc) injection | Form | 1/4/2022 |
| Thymoglobulin® [Anti-thymocyte Globulin (Rabbit)] | Form | 1/4/2022 |
| THYROGEN® (thyrotropin alfa for injection) | Form | 1/15/2021 |
House Bill 19-1131. Published by the General Assembly of the State of Colorado
Please See Full Prescribing Information, including Boxed Warning, for Aldurazyme, Aubagio, Elitek, Jevtana, Kevzara, Lemtrada, Lovenox, Lumizyme, Multaq, Nexviazyme, Thymoglobulin